BLTE 56.95 (+1.7%)
US07782B1044BiotechnologyBiotechnology

Belite Bio (BLTE) Stock Highlights

56.95 | +1.7%
2024-10-21 02:12:25
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

Statistics

Range Today
55.63 57.35
Volume Today 36.4K
Range 1 Year
30.21 56.5
Volume 1 Year 17.77M
Range 3 Year
8.8 56.5
Volume 3 Year 51.05M
Range 10 Year
8.8 56.5
Volume 10 Year 51.05M

Highlights

Market Capitalization 1.74B (small)
Floating Shares 12.67M
Current Price 56.95
Price To Earnings -45.23
Price To Book 15.22
Earnings Per Share -1.23
Payout Ratio 0%

Performance

Latest +1.7%
1 Month +17.98%
3 Months +17.16%
6 Months +76.59%
1 Year +76.75%
3 Years +355.6%
5 Years +355.6%
10 Years +355.6%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.